ULBP3

Summary

ULBP3 (UL16 binding protein 3, HGNC:14895) is a protein-coding gene on chromosome 6q25.1, encoding UL16-binding protein 3 (Q9BZM4). Binds and activates the KLRK1/NKG2D receptor, mediating natural killer cell cytotoxicity.

The protein encoded by this gene is one of several related ligands of the KLRK1/NKG2D receptor, which is found in primary NK cells. Binding of these ligands to the receptor activates several signal transduction pathways, including the JAK2, STAT5, and ERK pathways. The encoded protein is expressed solubly and on the surface of many tumor cells, making it potentially an important target for therapeutics.

Source: NCBI Gene 79465 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 40 total
• MANE Select transcript: NM_024518

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14895
Approved symbol	ULBP3
Name	UL16 binding protein 3
Location	6q25.1
Locus type	gene with protein product
Status	Approved
Aliases	RAET1N
Ensembl gene	ENSG00000131019
Ensembl biotype	protein_coding
OMIM	605699
Entrez	79465

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000367339, ENST00000438272, ENST00000925509

RefSeq mRNA: 1 — MANE Select: NM_024518 NM_024518

CCDS: CCDS5225

Canonical transcript exons

ENST00000367339 — 5 exons

Exon	Start	End
ENSE00000896364	150065398	150065673
ENSE00000896365	150065899	150066162
ENSE00001444256	150061053	150063351
ENSE00001444257	150068979	150069121
ENSE00003676003	150064585	150064713

Expression profiles

Bgee: expression breadth ubiquitous, 180 present calls, max score 79.61.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 3.4856 / max 75.2944, expressed in 1202 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
76165	2.7060	1107
76166	0.7795	475

Top tissues by expression

245 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.61	gold quality
kidney epithelium	UBERON:0004819	79.48	gold quality
epithelial cell of pancreas	CL:0000083	78.10	silver quality
cartilage tissue	UBERON:0002418	76.71	gold quality
stromal cell of endometrium	CL:0002255	76.49	gold quality
gingival epithelium	UBERON:0001949	74.96	gold quality
tibia	UBERON:0000979	74.38	gold quality
cortical plate	UBERON:0005343	74.05	gold quality
gingiva	UBERON:0001828	73.57	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	73.51	gold quality
esophagus squamous epithelium	UBERON:0006920	70.62	silver quality
ventricular zone	UBERON:0003053	70.06	gold quality
islet of Langerhans	UBERON:0000006	69.68	gold quality
pigmented layer of retina	UBERON:0001782	69.55	gold quality
cardiac muscle of right atrium	UBERON:0003379	69.34	gold quality
left ventricle myocardium	UBERON:0006566	69.17	gold quality
testis	UBERON:0000473	68.66	gold quality
ganglionic eminence	UBERON:0004023	68.50	gold quality
oral cavity	UBERON:0000167	68.42	gold quality
metanephros	UBERON:0000081	68.17	gold quality
parietal pleura	UBERON:0002400	66.78	silver quality
myocardium	UBERON:0002349	66.46	gold quality
Brodmann (1909) area 23	UBERON:0013554	66.46	silver quality
visceral pleura	UBERON:0002401	66.41	silver quality
jejunal mucosa	UBERON:0000399	66.24	silver quality
left testis	UBERON:0004533	66.08	gold quality
right testis	UBERON:0004534	66.03	gold quality
pancreatic ductal cell	CL:0002079	65.66	silver quality
tendon of biceps brachii	UBERON:0008188	65.54	silver quality
right adrenal gland cortex	UBERON:0035827	65.11	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.07

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

95 targeting ULBP3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-520G-5P	99.99	66.76	658
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-552-5P	99.93	68.56	1583
HSA-MIR-4778-3P	99.93	70.40	1818
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-22-3P	99.93	68.13	917
HSA-MIR-12133	99.92	71.82	2006
HSA-MIR-1271-5P	99.91	71.99	1972
HSA-MIR-454-3P	99.91	74.01	1925
HSA-MIR-6499-3P	99.90	66.38	1212
HSA-MIR-130A-3P	99.90	73.31	1861
HSA-MIR-130B-3P	99.90	73.27	1850

Literature-anchored findings (GeneRIF, showing 12)

• ULBP3 binds to the NGK2D receptor and activates multiple signaling pathways in primary natural killer cells. (PMID:11777960)
• ULBPs and MICA are expressed in lipid rafts at the cell surface of NK and T cells. (PMID:15051759)
• As NKG2D ligand, ULBP3 are expressed on immature and mature dendritic cells and plays an important role in the cytotoxic effect of NK cells against iDC. (PMID:18394338)
• Vpr specifically induces surface expression of the unique-long 16 binding proteins (ULBP)-1 and ULBP-2, but not ULBP-3 (PMID:19798433)
• genetic polymorphism among the ethnic groups (PMID:20219610)
• Data show that UL142 prevents ULBP3 trafficking to the surface and protects transfected cells from NK-mediated cytotoxicity. (PMID:20530255)
• A miRNA of the human JC and BK polyoma viruses targets the stress-induced ligand ULBP3 to escape immune elimination. (PMID:21320692)
• A greater expression of ULBP3 has also been found in hair follicles in scalp biopsy specimens from patients with active disease (PMID:21689246)
• This study provides for the first time, the c-Myc dependent regulation of NKG2D ligands, ULBP1/2/3 in acute myeloid leukemia. (PMID:24677544)
• Varicella-Zoster Virus differentially modulates expression of the NKG2D ligands by upregulating MICA expression and reducing ULBP2 and ULBP3 expression in the infected cells. (PMID:25995251)
• this study shows an increase in ULBP3 level in alopecia areata incognita patients, which positively correlates with the age and duration of the disease (PMID:27142445)
• Unveiling the role of the KLF4/Lnc18q22.2/ULBP3 axis in the tumorigenesis and immune escape of hepatocellular carcinoma under hypoxic condition. (PMID:38780505)

Cross-species orthologs

12 orthologs

Organism	Symbol	Gene ID
danio_rerio	mhc1laa	ENSDARG00000016056
danio_rerio	mhc1lba	ENSDARG00000016227
danio_rerio	mhc1lda	ENSDARG00000023203
danio_rerio		ENSDARG00000051710
danio_rerio		ENSDARG00000051711
danio_rerio	mhc1lfa	ENSDARG00000051712
danio_rerio	mhc1lga	ENSDARG00000051713
danio_rerio	mhc1lca	ENSDARG00000055813
danio_rerio	mhc1lja	ENSDARG00000096830
danio_rerio	si:dkey-52p2.5	ENSDARG00000096940
danio_rerio	mhc1lla	ENSDARG00000096977
mus_musculus	Ulbp1	ENSMUSG00000079685

Paralogs (22): HFE (ENSG00000010704), FCGRT (ENSG00000104870), ULBP1 (ENSG00000111981), ULBP2 (ENSG00000131015), MR1 (ENSG00000153029), RAET1L (ENSG00000155918), CD1D (ENSG00000158473), CD1A (ENSG00000158477), CD1C (ENSG00000158481), CD1B (ENSG00000158485), CD1E (ENSG00000158488), AZGP1 (ENSG00000160862), RAET1E (ENSG00000164520), RAET1G (ENSG00000203722), MICB (ENSG00000204516), MICA (ENSG00000204520), HLA-C (ENSG00000204525), HLA-E (ENSG00000204592), HLA-G (ENSG00000204632), HLA-F (ENSG00000204642), HLA-A (ENSG00000206503), HLA-B (ENSG00000234745)

Protein

Protein identifiers

UL16-binding protein 3 — Q9BZM4 (reviewed: Q9BZM4)

Alternative names: ALCAN-gamma, NKG2D ligand 3, Retinoic acid early transcript 1N

All UniProt accessions (1): Q9BZM4

UniProt curated annotations — full annotation on UniProt →

Function. Binds and activates the KLRK1/NKG2D receptor, mediating natural killer cell cytotoxicity.

Subunit / interactions. Interacts with KLRK1/NKG2D. Does not bind to beta2-microglobulin. (Microbial infection) In CMV-infected cells, interacts with the viral glycoprotein UL16 and UL142; this interaction causes ULBP3 retention in the endoplasmic reticulum and cis-Golgi and prevents binding to and activation of KLRK1/NKG2D, providing CMV with an immune evasion mechanism.

Subcellular location. Cell membrane.

Miscellaneous. UL16-binding proteins (ULBPs) are unusual members of the extended MHC class I superfamily. They do not contain the alpha 3 domain and lack a transmembrane domain.

Similarity. Belongs to the MHC class I family.

RefSeq proteins (1): NP_078794* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR011161	MHC_I-like_Ag-recog	Domain
IPR011162	MHC_I/II-like_Ag-recog	Homologous_superfamily
IPR037055	MHC_I-like_Ag-recog_sf	Homologous_superfamily
IPR050208	MHC_class-I_related	Family

Pfam: PF00129

UniProt features (23 total): strand 7, helix 5, turn 2, region of interest 2, disulfide bond 2, signal peptide 1, chain 1, propeptide 1, lipid moiety-binding region 1, glycosylation site 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
1KCG	X-RAY DIFFRACTION	2.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BZM4-F1	82.59	0.60

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 217

Disulfide bonds (2): 51–67, 128–191

Glycosylation sites (1): 37

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-198933	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell

MSigDB gene sets: 64 (showing top): GOBP_POSITIVE_REGULATION_OF_ADAPTIVE_IMMUNE_RESPONSE, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, GOBP_REGULATION_OF_ADAPTIVE_IMMUNE_RESPONSE, GOCC_CELL_SURFACE, GOBP_LEUKOCYTE_MEDIATED_CYTOTOXICITY, GOBP_ANTIGEN_PROCESSING_AND_PRESENTATION_VIA_MHC_CLASS_IB, GOBP_ANTIGEN_PROCESSING_AND_PRESENTATION_OF_PEPTIDE_ANTIGEN, GOBP_LEUKOCYTE_MEDIATED_IMMUNITY, GOBP_POSITIVE_REGULATION_OF_T_CELL_MEDIATED_CYTOTOXICITY, chr6q25, GOBP_REGULATION_OF_IMMUNE_RESPONSE, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, GOBP_LYMPHOCYTE_MEDIATED_IMMUNITY, GOBP_ANTIGEN_PROCESSING_AND_PRESENTATION, GOBP_REGULATION_OF_T_CELL_MEDIATED_CYTOTOXICITY

GO Biological Process (7): positive regulation of T cell mediated cytotoxicity (GO:0001916), antigen processing and presentation of endogenous peptide antigen via MHC class Ib (GO:0002476), antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent (GO:0002486), immune response (GO:0006955), natural killer cell activation (GO:0030101), natural killer cell mediated cytotoxicity (GO:0042267), immune system process (GO:0002376)

GO Molecular Function (2): natural killer cell lectin-like receptor binding (GO:0046703), protein binding (GO:0005515)

GO Cellular Component (5): obsolete extracellular space (GO:0005615), plasma membrane (GO:0005886), external side of plasma membrane (GO:0009897), membrane (GO:0016020), side of membrane (GO:0098552)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Adaptive Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
membrane	2
cellular anatomical structure	2
positive regulation of leukocyte mediated cytotoxicity	1
T cell mediated cytotoxicity	1
regulation of T cell mediated cytotoxicity	1
positive regulation of T cell mediated immunity	1
antigen processing and presentation of peptide antigen via MHC class Ib	1
antigen processing and presentation of endogenous peptide antigen	1
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway	1
immune system process	1
response to stimulus	1
lymphocyte activation	1
leukocyte mediated cytotoxicity	1
natural killer cell mediated immunity	1
biological_process	1
signaling receptor binding	1
binding	1
cell periphery	1
plasma membrane	1
cell surface	1
side of membrane	1
leaflet of membrane bilayer	1

Protein interactions and networks

STRING

600 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ULBP3	KLRK1	P26718	999
ULBP3	HCST	Q9UBK5	857
ULBP3	CD226	Q15762	798
ULBP3	NCR3	O14931	774
ULBP3	LILRB1	Q8NHL6	755
ULBP3	CCR8	P51685	717
ULBP3	NECTIN2	Q92692	693
ULBP3	PVR	P15151	681
ULBP3	KLRD1	Q13241	666
ULBP3	NCR1	O76036	646
ULBP3	PRDX5	P30044	642
ULBP3	B2M	P01884	617
ULBP3	NCR3LG1	Q68D85	609
ULBP3	SLAMF6	Q96DU3	595
ULBP3	STX17	P56962	592

IntAct

88 interactions, top by confidence:

A	B	Type	Score
ULBP3	KLRK1	psi-mi:“MI:0407”(direct interaction)	0.800
KLRK1	ULBP3	psi-mi:“MI:0407”(direct interaction)	0.800
ULBP3	KLRK1	psi-mi:“MI:0915”(physical association)	0.800
TNFSF8	TOR1B	psi-mi:“MI:0914”(association)	0.640
SLC39A5	FAM171A2	psi-mi:“MI:0914”(association)	0.640
FOS	ULBP3	psi-mi:“MI:0915”(physical association)	0.560
ULBP3	UQCRC1	psi-mi:“MI:0915”(physical association)	0.560
SLC39A5	TMEM223	psi-mi:“MI:0914”(association)	0.530
TMEM30B	KLRG2	psi-mi:“MI:0914”(association)	0.530
GJB7	PALM3	psi-mi:“MI:0914”(association)	0.530
IL13RA2	METTL15	psi-mi:“MI:0914”(association)	0.530
ULBP1	IGLL5	psi-mi:“MI:0914”(association)	0.530
FCGRT	GOLIM4	psi-mi:“MI:0914”(association)	0.530
CD1B	TOR1B	psi-mi:“MI:0914”(association)	0.530
CCNL2	ZBTB43	psi-mi:“MI:0914”(association)	0.530
HLA-DPA1	TYW5	psi-mi:“MI:0914”(association)	0.530
IL27RA	B4GALT5	psi-mi:“MI:0914”(association)	0.530

BioGRID (86): ULBP3 (Affinity Capture-MS), ULBP3 (Affinity Capture-MS), ULBP3 (Affinity Capture-MS), ULBP3 (Affinity Capture-MS), ULBP3 (Affinity Capture-MS), ULBP3 (Affinity Capture-MS), ULBP3 (Affinity Capture-MS), ULBP3 (Affinity Capture-MS), ULBP3 (Affinity Capture-MS), ULBP3 (Affinity Capture-MS), ULBP3 (Affinity Capture-MS), ULBP3 (Affinity Capture-MS), ULBP3 (Affinity Capture-MS), ULBP3 (Affinity Capture-MS), ULBP3 (Affinity Capture-MS)

ESM2 similar proteins: A0A0G2K7V7, C1ITJ8, O08602, O08603, O08604, O19477, O35799, P01901, P01902, P06339, P13599, P14427, P14432, P16391, P25311, P26151, P30383, P55899, P60018, P70387, Q01965, Q29980, Q29983, Q2KN22, Q30201, Q3B8P2, Q5RD09, Q60I18, Q61559, Q63678, Q64726, Q6H3X3, Q8HWB0, Q8HWE5, Q8HWE7, Q8SPV9, Q8VD31, Q920A9, Q95460, Q9BCU3

Diamond homologs: Q5VY80, Q6H3X3, Q8TD07, Q9BZM4, Q9BZM5, Q9BZM6

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 109 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	9	11.4×	3e-05

GO biological processes:

GO term	Partners	Fold	FDR
immune response	13	6.5×	6e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

40 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	34
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

725 predictions. Top by Δscore:

Variant	Effect	Δscore
6:150068975:TCA:T	donor_loss	1.0000
6:150068977:A:AG	donor_loss	1.0000
6:150063353:T:C	acceptor_gain	0.9900
6:150064584:CCTG:C	donor_gain	0.9900
6:150064714:C:CC	acceptor_gain	0.9900
6:150065393:GTTAC:G	donor_loss	0.9900
6:150065394:TTACC:T	donor_loss	0.9900
6:150065395:TACCT:T	donor_loss	0.9900
6:150065396:ACCT:A	donor_loss	0.9900
6:150065397:C:G	donor_loss	0.9900
6:150068747:T:TA	donor_gain	0.9900
6:150068972:AACT:A	donor_loss	0.9900
6:150068973:ACT:A	donor_loss	0.9900
6:150068977:A:AC	donor_gain	0.9900
6:150068977:ACCGG:A	donor_gain	0.9900
6:150068978:C:CC	donor_gain	0.9900
6:150068978:CCGG:C	donor_gain	0.9900
6:150068978:CCGGC:C	donor_gain	0.9900
6:150063349:CACCT:C	acceptor_gain	0.9800
6:150065419:T:TA	donor_gain	0.9800
6:150065675:T:A	acceptor_loss	0.9800
6:150065685:A:T	acceptor_gain	0.9800
6:150063351:CCT:C	acceptor_gain	0.9700
6:150063353:T:TC	acceptor_gain	0.9700
6:150064579:CAGTA:C	donor_loss	0.9700
6:150064580:AGTAC:A	donor_loss	0.9700
6:150064581:GTACC:G	donor_loss	0.9700
6:150064582:TACCT:T	donor_loss	0.9700
6:150064583:ACCTG:A	donor_loss	0.9700
6:150064584:C:CA	donor_loss	0.9700

AlphaMissense

1613 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:150065600:G:C	F142L	0.945
6:150065600:G:T	F142L	0.945
6:150065602:A:G	F142L	0.945
6:150065579:G:C	F149L	0.924
6:150065579:G:T	F149L	0.924
6:150065581:A:G	F149L	0.924
6:150065551:A:G	W159R	0.922
6:150065551:A:T	W159R	0.922
6:150065570:A:C	F152L	0.899
6:150065570:A:T	F152L	0.899
6:150065572:A:G	F152L	0.899
6:150066137:G:C	F38L	0.885
6:150066137:G:T	F38L	0.885
6:150066139:A:G	F38L	0.885
6:150065549:C:A	W159C	0.875
6:150065549:C:G	W159C	0.875
6:150065507:C:A	W173C	0.872
6:150065507:C:G	W173C	0.872
6:150065608:A:G	W140R	0.856
6:150065608:A:T	W140R	0.856
6:150065594:G:C	F144L	0.843
6:150065594:G:T	F144L	0.843
6:150065596:A:G	F144L	0.843
6:150066065:A:C	F62L	0.838
6:150066065:A:T	F62L	0.838
6:150066067:A:G	F62L	0.838
6:150065432:G:C	F198L	0.837
6:150065432:G:T	F198L	0.837
6:150065434:A:G	F198L	0.837
6:150065601:A:G	F142S	0.835

dbSNP variants (sampled 300 via entrez): RS1000147474 (6:150062654 G>A), RS1000433503 (6:150062910 G>A), RS1001139093 (6:150063991 C>G,T), RS1001644508 (6:150068672 A>C), RS1002315060 (6:150065270 C>G,T), RS1002630883 (6:150069722 A>G), RS1002980490 (6:150061416 C>G,T), RS1003639549 (6:150070888 G>A), RS1003996753 (6:150062565 T>C,G), RS1004432917 (6:150068223 A>G), RS1004607548 (6:150067247 G>C), RS1004886153 (6:150068059 T>G), RS1005385323 (6:150063702 C>T), RS1006003392 (6:150065136 G>A), RS1006492536 (6:150069641 T>G)

Disease associations

OMIM: gene MIM:605699 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST000719_3	Alopecia areata	4.000000e-19
GCST001818_3	Metabolite levels (HVA/5-HIAA ratio)	4.000000e-06
GCST004866_2	Alopecia areata	6.000000e-24
GCST012483_2	Cerebral amyloid angiopathy in APOEe4 non-carrier Alzheimer’s disease	4.000000e-06
GCST012484_3	Cerebral amyloid angiopathy x APOEe4 status interaction in Alzheimer’s disease	5.000000e-07

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0005131	HVA measurement
EFO:0005132	5-HIAA measurement
EFO:0007659	APOE carrier status

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

19 total (human), top 19 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects cotreatment, increases abundance, increases expression	2
Resveratrol	decreases reaction, increases expression	2
Benzo(a)pyrene	affects methylation, increases methylation	2
aristolochic acid I	increases expression	1
bisphenol A	decreases methylation	1
2-methyl-4-isothiazolin-3-one	increases expression	1
manganese chloride	increases abundance, increases expression, affects cotreatment	1
abrine	decreases expression	1
jinfukang	decreases expression	1
Sunitinib	decreases expression	1
Arsenic Trioxide	increases expression	1
Arsenic	increases expression, affects cotreatment, increases abundance	1
Caffeine	decreases reaction, increases expression	1
Estradiol	increases expression	1
Hydrogen Peroxide	increases expression	1
Manganese	increases abundance, increases expression, affects cotreatment	1
Smoke	decreases expression	1
Thiram	increases expression	1
Tobacco Smoke Pollution	increases expression	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B8AB	Abcam Raji ULBP3 KO	Cancer cell line	Male
CVCL_C0B6	Abcam THP-1 ULBP3 KO	Cancer cell line	Male
CVCL_C7CU	Abcam PC-3 ULBP3 KO	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.